Detalhe da pesquisa
1.
Absolute and Relative Psoriasis Area and Severity Indices (PASI) for Comparison of the Efficacy of Ixekizumab to Etanercept and Placebo in Patients with Moderate-to-severe Plaque Psoriasis: An Integrated Analysis of UNCOVER-2 and UNCOVER-3 Outcomes.
Acta Derm Venereol
; 99(11): 971-977, 2019 Oct 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31240322
2.
Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated data.
J Am Acad Dermatol
; 76(3): 432-440.e17, 2017 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-27889292
3.
Costs and quality of life for psoriatic patients at different degrees of severity in southern Sweden - a cross-sectional study.
Eur J Dermatol
; 22(2): 238-45, 2012.
Artigo
em Inglês
| MEDLINE | ID: mdl-22361745
4.
[Psoriasis is more than just a skin disease. Patients should be monitored for cardiovascular risk factor]. / Psoriasis är mer än bara en hudsjukdom. Patienter bör kontrolleras för kardiovaskulära riskfaktorer.
Lakartidningen
; 110(41): 1796-8, 2013.
Artigo
em Sueco
| MEDLINE | ID: mdl-24187892
5.
Psoriasis of the face and flexures.
J Dermatolog Treat
; 18(6): 351-60, 2007.
Artigo
em Inglês
| MEDLINE | ID: mdl-17907013
6.
Psoriasis: severity assessment in clinical practice. Conclusions from workshop discussions and a prospective multicentre survey of psoriasis severity.
Eur J Dermatol
; 16(2): 167-71, 2006.
Artigo
em Inglês
| MEDLINE | ID: mdl-16581570
7.
Progressive cutaneous sarcoidosis responding to anti-tumor necrosis factor-alpha therapy.
J Am Acad Dermatol
; 48(2): 290-3, 2003 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-12582407